DK2155248T3 - Målretning mod abcb5 til cancerterapi - Google Patents

Målretning mod abcb5 til cancerterapi Download PDF

Info

Publication number
DK2155248T3
DK2155248T3 DK08742787.8T DK08742787T DK2155248T3 DK 2155248 T3 DK2155248 T3 DK 2155248T3 DK 08742787 T DK08742787 T DK 08742787T DK 2155248 T3 DK2155248 T3 DK 2155248T3
Authority
DK
Denmark
Prior art keywords
abcb5
antibody
cells
seq
melanoma
Prior art date
Application number
DK08742787.8T
Other languages
English (en)
Inventor
Markus H Frank
Natasha Y Frank
Mohamed H Sayegh
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK2155248T3 publication Critical patent/DK2155248T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)

Claims (7)

1. Sammensætning til anvendelse til behandling af en person med melanom, hvilken sammensætning omfatter et anti-ABCB5-antistof eller et antigenbindende fragment deraf, der har mindst ét humant område, hvilket anti-ABCB5-antistof eller antigenbindende fragment deraf omfatter 1) et variabelt immunoglobulin-domæne af tung kæde, hvor: (i) CDR1-H1 omfatter en aminosyresekvens ifølge SEQ ID NO: 3; (ii) CDR2-H2 omfatter en aminosyresekvens ifølge SEQ ID NO: 4; og (i i i) CDR3-H3-sekvensen omfatter en aminosyresekvens ifølge SEQ ID NO: 5, og yderligere omfatter 2) et variabelt immunoglobulin-domæne af let kæde, hvor: (i) CDR1-L1 omfatter en aminosyresekvens ifølge SEQ ID NO: 6; (ii) CDR2-L2 omfatter en aminosyresekvens ifølge SEQ ID NO: 7; og (i i i) CDR3-L3-sekvensen omfatter en aminosyresekvens ifølge SEQ ID NO: 8.
2. Anvendelse af en sammensætning til fremstilling af et medikament til behandling af en person med melanom, hvilken sammensætning omfatter et anti-ABCB5-antistof eller et antigenbindende fragment deraf, der har mindst ét humant område, hvilket anti-ABCB5-antistof eller antigenbindende fragment deraf omfatter 1) et variabelt immunoglobulin-domæne af tung kæde, hvor: (i) CDR1-H1 omfatter en aminosyresekvens ifølge SEQ ID NO: 3; (ii) CDR2-H2 omfatter en aminosyresekvens ifølge SEQ ID NO: 4; og (i i i) CDR3-H3-sekvensen omfatter en aminosyresekvens ifølge SEQ ID NO: 5, og yderligere omfatter 2) et variabelt immunoglobulin-domæne af let kæde, hvor: (i) CDR1-L1 omfatter en aminosyresekvens ifølge SEQ ID NO: 6; (ii) CDR2-L2 omfatter en aminosyresekvens ifølge SEQ ID NO: 7; og (iii) CDR3-L3-sekvensen omfatter en aminosyresekvens ifølge SEQ ID NO: 8 .
3. Sammensætning ifølge krav 1 eller anvendelse ifølge krav 2, hvor antistoffet er en enkeltkædet Fv, et monoklonalt antistof, et bispecifikt antistof eller et syntetisk antistof.
4. Sammensætning ifølge krav 1 eller anvendelse ifølge krav 2, der omfatter mindst to variable antistofdomæner, der omfatter: (a) det variable antistofdomæne af tung kæde ifølge SEQ ID NO: 1; og (b) det variable antistof domæne af let kæde ifølge SEQ ID NO: 2.
5. Sammensætning ifølge krav 1 eller anvendelse ifølge krav 2, hvor antistoffet er et fuldstændigt humant isoleret antistof.
6. Sammensætning ifølge krav 1 eller anvendelse ifølge krav 2, der yderligere omfatter et dimeriseringsdomæne, der er koblet til det C-terminale område af et variabelt domæne af tung kæde-polypeptid.
7. Sammensætning ifølge krav 1 eller anvendelse ifølge krav 2, hvor anti-ABCB5-antistoffet eller det antigenbindende fragment deraf er et kimært antistof, der omfatter et variabelt domæne, der binder specifikt til ABCB5, og et konstant domæne, hvor det variable domæne og det konstante domæne er fra forskellige arter.
DK08742787.8T 2007-04-12 2008-04-11 Målretning mod abcb5 til cancerterapi DK2155248T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92312807P 2007-04-12 2007-04-12
US705907P 2007-12-11 2007-12-11
PCT/US2008/004715 WO2008127656A1 (en) 2007-04-12 2008-04-11 Targeting abcb5 for cancer therapy

Publications (1)

Publication Number Publication Date
DK2155248T3 true DK2155248T3 (da) 2015-09-14

Family

ID=39661432

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08742787.8T DK2155248T3 (da) 2007-04-12 2008-04-11 Målretning mod abcb5 til cancerterapi
DK13163810.8T DK2644205T3 (da) 2007-04-12 2008-04-11 Målretning af ABCB5 til cancerterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13163810.8T DK2644205T3 (da) 2007-04-12 2008-04-11 Målretning af ABCB5 til cancerterapi

Country Status (15)

Country Link
US (4) US7928202B2 (da)
EP (3) EP3431103B1 (da)
JP (4) JP5889527B2 (da)
AU (1) AU2008239633B2 (da)
CA (1) CA2718573C (da)
CY (2) CY1116823T1 (da)
DK (2) DK2155248T3 (da)
ES (2) ES2687270T3 (da)
HR (2) HRP20150934T1 (da)
HU (2) HUE039385T2 (da)
LT (1) LT2644205T (da)
PL (2) PL2644205T3 (da)
PT (2) PT2155248E (da)
SI (2) SI2644205T1 (da)
WO (1) WO2008127656A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290028B1 (en) 2000-06-05 2009-12-23 The Brigham And Women's Hospital, Inc. A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF
HUE059011T2 (hu) * 2006-05-31 2022-09-28 Childrens Medical Center Immunmodulátorként szolgáló ABC5-pozitív mezenchimális õssejtek
DK2155248T3 (da) 2007-04-12 2015-09-14 Brigham & Womens Hospital Målretning mod abcb5 til cancerterapi
PT3130923T (pt) * 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
US20110280862A1 (en) * 2010-05-14 2011-11-17 The University Of Hong Kong Gep and drug transporter regulation, cancer therapy and prognosis
AU2014219026B2 (en) 2013-02-19 2018-11-29 Children's Medical Center Corporation ABCB5(+) stem cells for treating ocular disease
EP4008369A1 (en) 2013-05-10 2022-06-08 Children's Medical Center Corporation Wound healing and tissue engineering
US9177410B2 (en) 2013-08-09 2015-11-03 Ayla Mandel System and method for creating avatars or animated sequences using human body features extracted from a still image
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2019210109A1 (en) * 2018-04-25 2019-10-31 Children's Medical Center Corporation Abcb5 ligands and substrates
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
KR20230004590A (ko) * 2020-04-15 2023-01-06 칠드런'즈 메디컬 센터 코포레이션 다형성 교모세포종에서의 abcb5 표적화
AU2021262864A1 (en) * 2020-04-30 2022-11-17 Children's Medical Center Corporation Antibodies specific to ABCB5 and uses thereof
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
WO1980001139A1 (en) * 1978-12-06 1980-06-12 Svedman Paul Device for treating tissues,for example skin
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
AT379688B (de) * 1982-11-22 1986-02-10 List Hans Sensorelement zur bestimmung des o2-gehaltes einer probe
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0174810B1 (en) 1984-09-10 1993-07-21 HSC Research Development Corporation Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
GB8509978D0 (en) * 1985-04-18 1985-05-30 Juhasz L Wound dressings
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5399483A (en) * 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6436078B1 (en) * 1994-12-06 2002-08-20 Pal Svedman Transdermal perfusion of fluids
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US6231881B1 (en) * 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
GB2272645B8 (en) * 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU704183B2 (en) 1994-01-05 1999-04-15 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
GB9403135D0 (en) * 1994-02-18 1994-04-06 Univ Glasgow Wound healing device
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2259386C (en) * 1996-06-28 2002-06-25 Matsushita Electric Works, Ltd. Modification apparatus
US5904659A (en) * 1997-02-14 1999-05-18 Exogen, Inc. Ultrasonic treatment for wounds
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE19722075C1 (de) * 1997-05-27 1998-10-01 Wilhelm Dr Med Fleischmann Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche
US6420622B1 (en) * 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
US6071267A (en) * 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB9808836D0 (en) * 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
JP4220058B2 (ja) * 1998-06-30 2009-02-04 浜松ホトニクス株式会社 半導体位置検出器
US6479072B1 (en) * 1999-02-11 2002-11-12 The General Hospital Corporation Microfabricated membranes and matrices
US6277574B1 (en) * 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney
PL366290A1 (en) * 1999-11-29 2005-01-24 Hill-Rom Services, Inc. Wound treatment apparatus
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
EP1290028B1 (en) * 2000-06-05 2009-12-23 The Brigham And Women's Hospital, Inc. A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF
AU2001268328A1 (en) * 2000-06-12 2001-12-24 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
CA2412494C (en) 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
AU2002211389A1 (en) * 2000-10-03 2002-04-15 California Institute Of Technology Microfluidic devices and methods of use
CA2427010A1 (en) 2000-10-27 2002-05-23 Incyte Genomics, Inc. Transporters and ion channels
US6685681B2 (en) * 2000-11-29 2004-02-03 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US6855135B2 (en) * 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US8015677B2 (en) 2000-12-01 2011-09-13 Aard-Balm Limited Embalming fluid
EP1350029B1 (en) * 2001-01-08 2014-09-10 President and Fellows of Harvard College Valves and pumps for microfluidic systems and method for making microfluidic systems
US6899873B2 (en) * 2001-02-02 2005-05-31 The Regents Of The University Of Michigan Method of forming micro-tubular polymeric materials
US6695824B2 (en) * 2001-04-16 2004-02-24 The United States Of America As Represented By The Secretary Of The Army Wound dressing system
WO2003057070A2 (en) * 2001-12-26 2003-07-17 Hill-Rom Services Inc. Vented vacuum bandage and method
AU2002359830A1 (en) * 2001-12-26 2003-07-24 Hill-Rom Services, Inc. Wound vacuum therapy dressing kit
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
US7829336B2 (en) 2003-11-24 2010-11-09 The Rockefeller University Method for isolating a self-renewing, multipotent, slow-cycling cell
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
US7364592B2 (en) * 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
WO2006051405A2 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
HUE059011T2 (hu) 2006-05-31 2022-09-28 Childrens Medical Center Immunmodulátorként szolgáló ABC5-pozitív mezenchimális õssejtek
CA2698597A1 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Monitoring cancer stem cells
DK2155248T3 (da) 2007-04-12 2015-09-14 Brigham & Womens Hospital Målretning mod abcb5 til cancerterapi
PT3130923T (pt) * 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
AU2014219026B2 (en) 2013-02-19 2018-11-29 Children's Medical Center Corporation ABCB5(+) stem cells for treating ocular disease
EP4008369A1 (en) 2013-05-10 2022-06-08 Children's Medical Center Corporation Wound healing and tissue engineering

Also Published As

Publication number Publication date
ES2547016T3 (es) 2015-09-30
HRP20181385T1 (hr) 2018-10-19
PT2155248E (pt) 2015-10-23
CY1116823T1 (el) 2017-03-15
HUE027593T2 (en) 2016-11-28
EP3431103A1 (en) 2019-01-23
PL2644205T3 (pl) 2018-11-30
EP2155248A1 (en) 2010-02-24
US20140302031A1 (en) 2014-10-09
JP6268237B2 (ja) 2018-01-24
AU2008239633B2 (en) 2014-05-29
JP5889527B2 (ja) 2016-03-22
SI2155248T1 (sl) 2015-12-31
HUE039385T2 (hu) 2018-12-28
JP2018052979A (ja) 2018-04-05
HRP20150934T1 (hr) 2015-11-06
JP2014133770A (ja) 2014-07-24
EP2644205B1 (en) 2018-06-13
WO2008127656A1 (en) 2008-10-23
PL2155248T3 (pl) 2015-12-31
AU2008239633A1 (en) 2008-10-23
US20090117117A1 (en) 2009-05-07
LT2644205T (lt) 2018-12-10
US8697072B2 (en) 2014-04-15
SI2644205T1 (sl) 2018-11-30
DK2644205T3 (da) 2018-09-24
EP2644205A1 (en) 2013-10-02
US9266946B2 (en) 2016-02-23
JP6530044B2 (ja) 2019-06-12
JP2016188248A (ja) 2016-11-04
US20160136297A1 (en) 2016-05-19
EP3431103B1 (en) 2021-07-28
US7928202B2 (en) 2011-04-19
ES2687270T3 (es) 2018-10-24
CA2718573C (en) 2020-07-14
US20110165149A1 (en) 2011-07-07
PT2644205T (pt) 2018-10-19
CA2718573A1 (en) 2008-10-23
JP2010534191A (ja) 2010-11-04
EP2155248B1 (en) 2015-06-10
US9855342B2 (en) 2018-01-02
CY1121046T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
DK2155248T3 (da) Målretning mod abcb5 til cancerterapi
RU2426744C2 (ru) Антитела к ox40l и способы их применения
TWI392503B (zh) 抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
KR101712214B1 (ko) 항-노치2 항체 및 사용 방법
JP5042631B2 (ja) アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法
KR20120057565A (ko) 항-ＦｃＲＨ５ 항체 및 면역접합체 및 사용 방법
TW201106972A (en) Combination treatments
CA2716321A1 (en) Methods for treating cancer using combination therapy
TW201121566A (en) Anti-hepsin antibodies and methods using same
AU2013204245B2 (en) Targeting abcb5 for cancer therapy
HK40004060B (en) Targeting abcb5 for cancer therapy
HK40004060A (en) Targeting abcb5 for cancer therapy
TWI429655B (zh) 抗egfl7抗體、包含其之組合物、編碼其之多核苷酸及其製造及使用方法
HK40034624A (en) Anti-cd79b antibodies and immunoconjugates and methods of use